[Effectiveness and tolerability of selegiline in the treatment of pathological cerebral involutions].
A dysfunction of dopaminergic systems with reduction of active dopamine, is well-known in cerebral involution. Twenty patients with mild-moderate pathological cerebral involution of atrophic and/or vascular origin, were treated with Selegiline (L-deprenyl), a monoamino-oxidase B inhibitor (10 mg/die for six months). Compared with a control group, Selegiline treated patients showed a statistically significant improvement in cognitive and behaviour capacities. At the end of investigation, "Mini Mental State" showed an improvement of 26.5% in Selegiline group and of 3.7% in control group (P < 0.01). "Echelle Clinique d'Aptitudes Intellectuelles" showed an improvement of 29.4% and of 10.8% respectively (P < 0.01). Selegiline treatment has shortened significantly the reaction times and has improved mnesic capacities. No side effects were observed during the study.
Bettini
R
R
Ospedale di Circolo, Università degli Studi dell'Insubria, Varese, Italia.
Gorini
M
M
D000368:Aged; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000175:diagnosis / Q000188:drug therapy; D001523:Mental Disorders / Q000175:diagnosis / Q000188:drug therapy*; D008609:Mental Status Schedule; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D011581:Psychological Tests; D011594:Psychometrics; D012642:Selegiline / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D008996:Monoamine Oxidase Inhibitors; D010919:Placebos; D012642:Selegiline